A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

Inclusion Criteria:

Written informed consent
Male and female patients aged 18 years or older
A history of uveal (ocular) melanoma with biopsy-confirmed metastatic disease
Consent to providing 3 tumor biopsy samples throughout the course of the study
Presence of measurable disease
A WHO performance status of less than or equal to 1

Exclusion Criteria:

Presence of CNS lesions (stable lesions may be acceptable)
Previous or concurrent malignancy, other than basal cell or squamous cell carcinoma of the skin: in situ carcinoma of the cervix, without evidence of recurrence for at least 3 years; a primary malignancy completely resected and no evidence of recurrence for at least 3 years
Adverse event from prior chemotherapy, radiotherapy or surgery that has not recovered to CTCAE v4.03 Grade 1 or less, except for alopecia/sensory peripheral neuropathy, which must be less than Grade 2
History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
Impaired cardiac function or clinically significant cardiac disease
Impaired GI function or disease that could interfere with the absorption of AEB071 and/or MEK162
Treatment with medicines or herbal supplements that are known inhibitors or inducers of CYP3A4/5 and cannot be withdrawn prior to study treatment
Females of child-bearing potential who are unwilling or unable to use highly effective means of contraception
Males who are unwilling or unable to use a condom during sexual intercourse
Prior exposure to a MEK or PKC inhibitor Other inclusion/exclusion criteria apply